The Australian Red Cross Lifeblood (Lifeblood) has implemented the removal of the indefinite geographical deferral for donors at risk of variant Creutzfeldt-Jakob Disease (vCJD) following approval from Australia’s Therapeutic Goods Administration (TGA)
The decision for this change was based on current clinical and scientific evidence and was reviewed by external medical experts.
At all times, patient safety remains the highest priority in any decision relating to donor changes to deferral periods.
Further information on this change is available at Lifeblood’s website, here and the TGA website here.
Print